E. Usala

发表

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

M. Lalowski, M. Baumann, F. Passamonti, 2018, Nature Communications.

NESTED DUPLEX PCR BCR / ABL ( B 2 A 2 , B 3 A 2 ) IN COMPLETE AUTOMATIZED SYSTEM

E. Angelucci, D. Cardia, E. Usala, 2009 .

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia

S. Moretti, S. Russo, G. Caocci, 2019, Cytometry. Part B, Clinical cytometry.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis

R. Foà, E. Orlandi, F. Efficace, 2018, American journal of hematology.

phase 1/2 study in patients with myelofibrosis Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a

P. Guglielmelli, A. Pancrazzi, A. Bosi, 2012 .

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2011, Blood.

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

R. Latagliata, V. Martinelli, L. Gugliotta, 2009, American journal of hematology.

Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations

P. Piccaluga, K. Ballen, D. DeAngelo, 2010, American journal of hematology.

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.

R. Fanin, P. Mazza, M. Baccarani, 2010, Blood.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

G. Rosti, A. Bosi, L. Puccetti, 2018, Front. Oncol..

Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting

G. Caocci, G. la Nasa, O. Mulas, 2020, International Journal of Hematology.

thrombocytopenia than dexamethasone monotherapy in adults with primary immune Dexamethasone plus rituximab yields higher sustained response rates

R. Fanin, P. Mazza, M. Baccarani, 2011 .

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

M. Baccarani, G. Rosti, G. Martinelli, 2015, Haematologica.

Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

R. Fanin, M. Baccarani, G. Martinelli, 2007, Bone Marrow Transplantation.

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.

V. Martinelli, A. Vannucchi, M. Mazzucconi, 2011, Leukemia research.

Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.

R. Fanin, M. Baccarani, G. Rosti, 2004 .

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.

M. Gobbi, G. Gaidano, C. Gambacorti-Passerini, 2015, Leukemia research.

The BCR‐ABL1 transcript type influences response and outcome in Philadelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib

F. Gherlinzoni, M. Baccarani, G. Rosti, 2017, American journal of hematology.

p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.

S. Perrotta, F. Della Ragione, A. Borriello, 2011, Carcinogenesis.

Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia

M. Baccarani, G. Rosti, G. Martinelli, 2016, American journal of hematology.

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

M. Baccarani, G. Martinelli, S. Russo, 2015, Blood Cancer Journal.

Reproducibility of liver iron concentration measured on a biopsy sample: A validation study in vivo

M. Capasso, D. Baronciani, E. Angelucci, 2015, American journal of hematology.

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

P. Campbell, G. Bignell, M. Cazzola, 2015, Blood.

LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY

M. Baccarani, G. Martinelli, G. Saglio, 2015 .

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

M. Fumagalli, M. Merli, S. Redaelli, 2020, HemaSphere.

F. Cottone, F. Efficace, G. Caocci, 2022, Annals of Hematology.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

M. Lalowski, M. Baumann, F. Passamonti, 2018, Nature Communications.

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up

R. Fanin, P. Mazza, M. Baccarani, 2008 .

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

G. Specchia, M. Gobbi, R. Fanin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP

R. Fanin, P. Mazza, M. Baccarani, 2007 .